Premium
Regulatory Aspects of New Medicines Targeted at Treatment of Autoimmune Diseases
Author(s) -
Hull K M,
Yim S
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.5
Subject(s) - clinical pharmacology , medicine , immunology , autoantibody , immune system , inflammation , pharmacology , antibody
Autoimmune diseases comprise a diverse group of clinical dis orders that result from the body's adaptive immune system reacting against its own tissues. 1 Conversely, autoinflammatory disorders encompass a more limited group of diseases distinguished by recurrent episodes of inflammation but in the absence of high‐titer autoantibodies and antigen‐specific T cells. 2 The past 15 years have seen a tremendous growth in the development of highly effective treatments for these diseases. Clinical Pharmacology & Therapeutics (2012); 91 4, 739–742. doi: 10.1038/clpt.2012.5